

Department of Biotechnology Ministry of Science & Technology

INDIA-PACT PROGRAMME (PARTNERSHIPS FOR ACCELERATING **CLINICAL TRIALS**)

NATIONAL PARTNERS

0=



Ministry of External Affairs



Ministry of Health and Family Welfare





Central Drugs Standard Control Organisation



INTERNATIONAL PARTNERS

CEPI





IMPLEMENTED BY











India not only has the capacity to contribute to the global health efforts, but also has the will to do so in a spirit of sharing and caring ??

- Honourable Prime Minister Narendra Modi at the Vaccine Summit in London on June 4, 2020

PACT: A SCIENCE DIPLOMACY INITIATIVE



Multilateral collaborations and partnerships for making available a safe and effective vaccine for COVID-19

Ind-CEPI

'India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development'


Centralised Immunoassay

THSTI, Faridabad recognized by CEPI as one of the 6 global network of laboratories for centralized assessment of COVID- 19 Vaccines

LMIC Benefits

Supporting efforts for advancing clinical trial capacity in neighbouring countries and LMICs

PHASE III CLINICAL TRIALS OF INDIAN COVID VACCINES IN NEIGHBOURING AND FRIENDLY COUNTRIES



Advisory support for planning and executing Phase III trials for LMICs

Access to Indian Vaccine development Ecosystem specially exploring immunogenicity assay testing of potential vaccine candidates Acceleration of indigenous vaccine development efforts

STRENGTHENING CLINICAL RESEARCH CAPACITY IN NEIGHBOURING COUNTRIES UNDER THE IND-CEPI MISSION



Objective:

To support researchers and investigator teams of neighbouring countries to enhance and strengthen their clinical trial capabilities so that the conduct of trials is in compliance with ICH-GCP guidelines. This program is being steered by BIRAC and CDSA

Sessions Covered:

Good Clinical Practice (GCP), Ethical considerations in Clinical Research, Good Clinical Laboratory Practice (GCLP) and Large Vaccine Trials.

Access to Indian Vaccine development Ecosystem specially exploring immunogenicity assay testing of potential vaccine candidates



Target audience:

Investigators, coinvestigators, health workers, technicians, nurses and support staff from hospitals, community health centres, other health agencies and field sites.